"Vaccines, Synthetic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
Descriptor ID |
D014614
|
MeSH Number(s) |
D12.776.828.868 D20.215.894.865 D23.050.865
|
Concept/Terms |
Vaccines, Synthetic- Vaccines, Synthetic
- Synthetic Vaccines
- Synthetic Immunogens
- Immunogens, Synthetic
Molecular Vaccines- Molecular Vaccines
- Vaccines, Molecular
- Vaccines, Chemical
- Chemical Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Vaccines, Synthetic".
Below are MeSH descriptors whose meaning is more specific than "Vaccines, Synthetic".
This graph shows the total number of publications written about "Vaccines, Synthetic" by people in this website by year, and whether "Vaccines, Synthetic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 3 | 1 | 4 |
1996 | 7 | 3 | 10 |
1997 | 3 | 3 | 6 |
1998 | 4 | 2 | 6 |
1999 | 5 | 1 | 6 |
2000 | 1 | 4 | 5 |
2001 | 1 | 1 | 2 |
2002 | 2 | 4 | 6 |
2003 | 3 | 2 | 5 |
2004 | 2 | 5 | 7 |
2005 | 2 | 3 | 5 |
2006 | 2 | 3 | 5 |
2007 | 3 | 3 | 6 |
2008 | 1 | 4 | 5 |
2009 | 0 | 4 | 4 |
2010 | 2 | 3 | 5 |
2011 | 1 | 1 | 2 |
2012 | 1 | 7 | 8 |
2013 | 0 | 2 | 2 |
2014 | 1 | 4 | 5 |
2015 | 1 | 5 | 6 |
2016 | 0 | 7 | 7 |
2017 | 2 | 7 | 9 |
2018 | 2 | 2 | 4 |
2019 | 0 | 1 | 1 |
2020 | 1 | 6 | 7 |
2021 | 2 | 14 | 16 |
2022 | 1 | 17 | 18 |
2023 | 0 | 3 | 3 |
2024 | 0 | 2 | 2 |
2025 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vaccines, Synthetic" by people in Profiles.
-
rVSV?G-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model. Viruses. 2025 Feb 28; 17(3).
-
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis. 2025 02 05; 80(1):223-227.
-
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost. Nat Commun. 2025 Jan 17; 16(1):759.
-
Altering the intracellular trafficking of Necator americanus GST-1 antigen yields novel hookworm mRNA vaccine candidates. PLoS Negl Trop Dis. 2025 Jan; 19(1):e0012809.
-
Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-na?ve adults. PLoS Negl Trop Dis. 2024 Dec; 18(12):e0012788.
-
Determination of T cell response against XBB variants in adults who received either monovalent wild-type inactivated whole virus or mRNA vaccine or bivalent WT/BA.4-5 COVID-19 mRNA vaccine as the additional booster. Int J Infect Dis. 2024 Dec; 149:107271.
-
A Journey in Science: Molecular vaccines for global child health in troubled times of anti-science. Mol Med. 2024 Mar 15; 30(1):37.
-
Broad protective vaccination against systemic Escherichia coli with autotransporter antigens. PLoS Pathog. 2023 02; 19(2):e1011082.
-
Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial. Clin Infect Dis. 2023 02 08; 76(3):e1168-e1176.
-
Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters. N Engl J Med. 2023 02 09; 388(6):565-567.